Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax PK with Phenytoin or Itraconazole in Healthy Subjects
NCT06543043Phase 1Completed
- Sponsor
- BeiGene
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sonrotoclax in B cell malignancies (2 arms), sponsored by BeiGene. Primary endpoints: Lag time before observation of quantifiable concentrations at 11 days, Time to maximum observed concentration at 11 days and 3 more. Started Aug 2024; status: completed.
02
Drugs
sonrotoclax
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT06543043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543043.